Cadila Healthcare receives EIR from USFDA for Baddi facility
The EIR report stated that the classification of the facility is no action indicated (NAI), it added
Advertisement
New Delhi: Drug firm Cadila Healthcare on Thursday said its manufacturing facility at Baddi in Himachal Pradesh has received an establishment inspection report (EIR) from the US health regulator with no action indicated classification.
The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from March 2 to 9. The audit had ended with nil observations, Cadila Healthcare said in a filing to BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.